Skip to main content

Advertisement

SpringerLink
Log in

PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Glioblastoma(GBM) is the most common primary tumor of the central nervous system with an extremely dismal prognosis. Many progresses have been made such as the discovery of new molecular biomarkers and target drugs especially IDH inhibitors. However, GBM prognosis is still poor, which requires more biomarkers and drug targets for more precision classification and treatment.

Materials and methods

Potential prognostic biomarkers of GBM were screened by TCGA database, and ectopic up-regulation of PARP14 was identified. Expression and clinical significance of PARP14 were detected in our GBM cohort consisting of 143 patients with gross total surgical resection. Related genes with PARP14 were further screened and identified by in silico analysis and in vitro experiments. The expression and prognostic significance of SAMD9 and SAMD9L were verified with IHC and survival analysis in our cohort.

Results

PARP14 was up-regulated in GBM compared with non-tumor adjacent tissues. PARP14 correlated with poor prognosis and can be regarded as an independent prognostic biomarker of GBM. PARP14 expression was positively associated with SAMD9 and SAMD9L in GBM. In GBM cells, PARP14 could increase the expression of SAMD9 and SAMD9L. SAMD9 and SAMD9L were highly expressed in high-PARP14 subset and were both prognostic biomarkers of GBM. Moreover, PARP14 increased GBM proliferation by inducing SAMD9 and SAMD9L expression.

Conclusions

PARP14, SAMD9, and SAMD9L are prognostic biomarkers of GBM predicting poor prognosis. PARP14 promotes GBM cell proliferation by inducing SAMD9 and SAMD9L expression. Our results indicate that PARP14/SAMD9/SAMD9L are prognostic biomarkers and potential drug targets of GBM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jacob F, Salinas RD, Zhang DY et al (2020) A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180(1):188–204 e122. https://doi.org/10.1016/j.cell.2019.11.036

  2. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106

  3. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310(17):1842–1850. https://doi.org/10.1001/jama.2013.280319

    Article  CAS  PubMed  Google Scholar 

  4. Yang K, Wu Z, Zhang H et al (2022) Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer 21(1):39. https://doi.org/10.1186/s12943-022-01513-z

  5. Alexander BM, Cloughesy TF (2017) Adult glioblastoma. J Clin Oncol 35(21):2402–2409. https://doi.org/10.1200/JCO.2017.73.0119

    Article  CAS  PubMed  Google Scholar 

  6. Ahel I, Ahel D, Matsusaka T et al (2008) Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451(7174):81–85. https://doi.org/10.1038/nature06420

    Article  CAS  PubMed  Google Scholar 

  7. Herceg Z, Wang ZQ (2001) Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 477(1–2):97–110. https://doi.org/10.1016/s0027-5107(01)00111-7

    Article  CAS  PubMed  Google Scholar 

  8. Langelier MF, Ruhl DD, Planck JL et al (2010) The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J Biol Chem 285(24):18877–18887. https://doi.org/10.1074/jbc.M110.105668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Maruyama T, Nara K, Yoshikawa H, Suzuki N (2007) Txk, a member of the non-receptor tyrosine kinase of the Tec family, forms a complex with poly(ADP-ribose) polymerase 1 and elongation factor 1alpha and regulates interferon-gamma gene transcription in Th1 cells. Clin Exp Immunol 147(1):164–175. https://doi.org/10.1111/j.1365-2249.2006.03249.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Reinemund J, Seidel K, Steckelings UM et al (2009) Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem Pharmacol 77(12):1795–1805. https://doi.org/10.1016/j.bcp.2009.02.025

  11. Ahel D, Horejsi Z, Wiechens N et al (2009) Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325(5945):1240–1243. https://doi.org/10.1126/science.1177321

  12. Barazzuol L, Jena R, Burnet NG et al (2013) Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8:65. https://doi.org/10.1186/1748-717X-8-65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Clarke MJ, Mulligan EA, Grogan PT et al (2009) Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8(2):407–414. https://doi.org/10.1158/1535-7163.MCT-08-0854

  14. Fugger K, Hewitt G, West SC, Boulton SJ (2021) Tackling PARP inhibitor resistance. Trends. Cancer 7(12):1102–1118. https://doi.org/10.1016/j.trecan.2021.08.007

    Article  CAS  Google Scholar 

  15. Slade D (2020) PARP and PARG inhibitors in cancer treatment. Genes Dev 34(5–6):360–394. https://doi.org/10.1101/gad.334516.119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gupta SK, Kizilbash SH, Carlson BL et al (2016) Delineation of MGMT Hypermethylation as a Biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst 108(5). https://doi.org/10.1093/jnci/djv369

  17. Aguiar RC, Takeyama K, He C et al (2005) B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem 280(40):33756–33765. https://doi.org/10.1074/jbc.M505408200

    Article  CAS  PubMed  Google Scholar 

  18. Iwata H, Goettsch C, Sharma A et al (2016) PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat Commun 7:12849. https://doi.org/10.1038/ncomms12849

  19. Kleine H, Poreba E, Lesniewicz K et al (2008) Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell 32(1):57–69. https://doi.org/10.1016/j.molcel.2008.08.009

  20. Vyas S, Matic I, Uchima L et al (2014) Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Commun 5:4426. https://doi.org/10.1038/ncomms5426

  21. Feijs KL, Verheugd P, Luscher B (2013) Expanding functions of intracellular resident mono-ADP-ribosylation in cell physiology. FEBS J 280(15):3519–3529. https://doi.org/10.1111/febs.12315

    Article  CAS  PubMed  Google Scholar 

  22. Cho SH, Ahn AK, Bhargava P et al (2011) Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. Proc Natl Acad Sci U S A 108(38):15972–15977. https://doi.org/10.1073/pnas.1017082108

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mehrotra P, Riley JP, Patel R et al (2011) PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. J Biol Chem 286(3):1767–1776. https://doi.org/10.1074/jbc.M110.157768

    Article  CAS  PubMed  Google Scholar 

  24. Iansante V, Choy PM, Fung SW et al (2015) PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun 6:7882. https://doi.org/10.1038/ncomms8882

  25. Mashimo M, Shimizu A, Mori A et al (2022) PARP14 regulates EP4 receptor expression in human colon cancer HCA-7 cells. Biochem Biophys Res Commun 623:133–139. https://doi.org/10.1016/j.bbrc.2022.07.055

  26. Yao N, Chen Q, Shi W et al (2019) PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-kappaB pathway. Mol Carcinog 58(7):1291–1302. https://doi.org/10.1002/mc.23011

    Article  CAS  PubMed  Google Scholar 

  27. Zhu Y, Liu Z, Wan Y et al (2022) PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1alpha expression. Clin Immunol 242:109094. https://doi.org/10.1016/j.clim.2022.109094

  28. Tan AC, Ashley DM, Lopez GY et al (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70(4):299–312. https://doi.org/10.3322/caac.21613

    Article  PubMed  Google Scholar 

  29. O’Connor MJ, Thakar T, Nicolae CM, Moldovan GL (2021) PARP14 regulates cyclin D1 expression to promote cell-cycle progression. Oncogene 40(30):4872–4883. https://doi.org/10.1038/s41388-021-01881-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chambon P, Weill JD, Mandel P (1963) Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39–43. https://doi.org/10.1016/0006-291x(63)90024-x

    Article  CAS  PubMed  Google Scholar 

  31. Weill JD, Busch S, Chambon P, Mandel P (1963) The effect of estradiol injections upon chicken liver nuclei ribonucleic acid polymerase. Biochem Biophys Res Commun 10:122–126. https://doi.org/10.1016/0006-291x(63)90036-6

    Article  CAS  PubMed  Google Scholar 

  32. Li CF, MacDonald JR, Wei RY et al (2007) Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics 8:92. https://doi.org/10.1186/1471-2164-8-92

  33. Narumi S, Amano N, Ishii T et al (2016) SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7. Nat Genet 48(7):792–797. https://doi.org/10.1038/ng.3569

  34. Chen DH, Below JE, Shimamura A et al (2016) Ataxia-pancytopenia syndrome is caused by missense mutations in SAMD9L. Am J Hum Genet 98(6):1146–1158. https://doi.org/10.1016/j.ajhg.2016.04.009

  35. Tesi B, Davidsson J, Voss M et al (2017) Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood 129(16):2266–2279. https://doi.org/10.1182/blood-2016-10-743302

  36. Russell AJ, Gray PE, Ziegler JB et al (2021) SAMD9L autoinflammatory or ataxia pancytopenia disease mutations activate cell-autonomous translational repression. Proc Natl Acad Sci USA 118(34). https://doi.org/10.1073/pnas.2110190118

  37. Schwartz JR, Ma J, Lamprecht T et al (2017) The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun 8(1):1557. https://doi.org/10.1038/s41467-017-01590-5

  38. Zhang F, Meng X, Townsend MB et al (2019) Identification of CP77 as the third Orthopoxvirus SAMD9 and SAMD9L inhibitor with unique specificity for a rodent SAMD9L. J Virol 93(12). https://doi.org/10.1128/JVI.00225-19

  39. Asou H, Matsui H, Ozaki Y et al (2009) Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun 383(2):245–251. https://doi.org/10.1016/j.bbrc.2009.04.004

  40. Wu L, Pu X, Wang Q et al (2016) miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncol Lett 11(2):945–952. https://doi.org/10.3892/ol.2015.4000

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Lei Zhang and Wenzhen Chen contributed equally.

Authors and Affiliations

  1. Department of Neurosurgery, the Second Affiliated Hospital of Shandong First Medical University, #706 Taishan Street, Tai’an, Shandong, 271000, China

    Lei Zhang & Zhende Shang

  2. Department of Neurointensive Care Unit, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China

    Wenzhen Chen

  3. Department of Neurosurgery, Dongping County People’s Hospital, Tai’an, China

    Zhaokun Shi

Authors
  1. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenzhen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhaokun Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhende Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhende Shang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 15 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Chen, W., Shi, Z. et al. PARP14 correlates with GBM proliferation and poor prognosis by elevating expression of SAMD/SAMD9L. Ir J Med Sci 193, 585–593 (2024). https://doi.org/10.1007/s11845-023-03500-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-023-03500-9

Keywords

Search

Navigation